Innova Therapeutics is a biotechnology company based in Mt Pleasant, SC, dedicated to developing innovative cancer therapies for patients with limited treatment options. Their monoclonal antibody platform targets a protein highly expressed in various solid cancers, with a lead humanized antibody designated as IVT-8086. Innova's platform technology initially focuses on pediatric osteosarcoma, sarcomas, breast cancer, and pancreatic cancer, with potential expansion to other solid tumors. They are also developing a diagnostic tool for early cancer detection and assessing treatment benefit and cancer recurrence.
The management team at Innova Therapeutics includes Dr. Robert Ryan, CEO, who has over 30 years of experience in research pharmaceutical biotech; Dr. Ron Nardi, Executive VP Development, with extensive experience in drug discovery and development; Michael Zimmer, CFO, a highly experienced executive in finance and operations; Dr. Nancy DeMore, Co-Founder and Clinical and Scientific Consultant, a surgical oncologist with expertise in tumor angiogenesis and immunology; and Willistine Lenon, Executive VP Clinical Operations, with over 27 years of experience in clinical operations in the pharmaceutical contract research organization industry globally.
Generated from the website